News | November 14, 2025
Novartis opens radioligand therapy facility in Carlsbad, US
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Subscribe To Our Newsletter & Stay Updated
